KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Liabilities and Shareholders Equity (2016 - 2025)

Idexx Laboratories (IDXX) has 17 years of Liabilities and Shareholders Equity data on record, last reported at $3.4 billion in Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity changed N/A year-over-year to $3.4 billion; the TTM value through Dec 2025 reached $6.6 billion, down 34.4%, while the annual FY2024 figure was $3.3 billion, 1.03% up from the prior year.
  • Liabilities and Shareholders Equity reached $3.4 billion in Q3 2025 per IDXX's latest filing, up from $3.2 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $3.4 billion in Q2 2024 and bottomed at $2.4 billion in Q4 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $3.1 billion, with a median of $3.2 billion recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: grew 19.41% in 2024, then decreased 4.17% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $2.4 billion in 2021, then rose by 12.7% to $2.7 billion in 2022, then rose by 18.68% to $3.3 billion in 2023, then increased by 1.03% to $3.3 billion in 2024, then grew by 2.83% to $3.4 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $3.4 billion in Q3 2025, $3.2 billion in Q1 2025, and $3.3 billion in Q4 2024.